LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

Search

Simulations Plus Inc

Închisă

SectorSănătate

11.37 -6.42

Rezumat

Modificarea prețului

24h

Curent

Minim

11.11

Maxim

11.6

Indicatori cheie

By Trading Economics

Venit

1.4M

676K

Vânzări

961K

18M

P/E

Medie Sector

48.528

110.024

EPS

-0.034

Randament dividend

0.48

Marjă de profit

3.67

Angajați

212

EBITDA

-3M

2.3M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+62.95% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.48%

2.26%

Următoarele câștiguri

2 apr. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-120M

248M

Deschiderea anterioară

17.79

Închiderea anterioară

11.37

Sentimentul știrilor

By Acuity

50%

50%

149 / 351 Clasament în Healthcare

Simulations Plus Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 feb. 2026, 22:53 UTC

Achiziții, Fuziuni, Preluări

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 feb. 2026, 22:36 UTC

Câștiguri

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 feb. 2026, 22:32 UTC

Câștiguri

Woodside Energy Fiscal Year Net Profit Falls 24%

23 feb. 2026, 23:58 UTC

Market Talk
Câștiguri

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 feb. 2026, 23:58 UTC

Market Talk
Câștiguri

Global Energy Roundup: Market Talk

23 feb. 2026, 23:47 UTC

Market Talk

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 feb. 2026, 23:43 UTC

Market Talk

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 feb. 2026, 23:41 UTC

Achiziții, Fuziuni, Preluări

Crescent Capital Partners Owns 53% of ClearView Wealth

23 feb. 2026, 23:40 UTC

Achiziții, Fuziuni, Preluări

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 feb. 2026, 23:40 UTC

Achiziții, Fuziuni, Preluări

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 feb. 2026, 23:40 UTC

Market Talk

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 feb. 2026, 23:40 UTC

Achiziții, Fuziuni, Preluări

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 feb. 2026, 23:39 UTC

Achiziții, Fuziuni, Preluări

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 feb. 2026, 23:31 UTC

Câștiguri

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 feb. 2026, 23:31 UTC

Câștiguri

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 feb. 2026, 23:28 UTC

Câștiguri

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 feb. 2026, 23:28 UTC

Câștiguri

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 feb. 2026, 23:28 UTC

Câștiguri

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 feb. 2026, 23:27 UTC

Câștiguri

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 feb. 2026, 23:24 UTC

Market Talk

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 feb. 2026, 22:38 UTC

Achiziții, Fuziuni, Preluări

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 feb. 2026, 22:31 UTC

Câștiguri

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 feb. 2026, 22:24 UTC

Câștiguri

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 feb. 2026, 22:22 UTC

Câștiguri

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 feb. 2026, 22:22 UTC

Câștiguri

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 feb. 2026, 22:22 UTC

Câștiguri

Viva Energy FY Underlying Ebitda A$700.9 Million

23 feb. 2026, 22:22 UTC

Câștiguri

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 feb. 2026, 22:21 UTC

Câștiguri

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 feb. 2026, 22:21 UTC

Câștiguri

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 feb. 2026, 22:20 UTC

Câștiguri

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Comparație

Modificare preț

Simulations Plus Inc Așteptări

Obiectiv de preț

By TipRanks

62.95% sus

Prognoză pe 12 luni

Medie 19 USD  62.95%

Maxim 19 USD

Minim 19 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSimulations Plus Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

4 ratings

2

Cumpărare

2

Păstrare

0

Vânzare

Sentiment

By Acuity

149 / 351 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat